Show simple item record

dc.contributor.authorKarol, SE
dc.contributor.authorSun, Y
dc.contributor.authorTang, L
dc.contributor.authorPui, C-H
dc.contributor.authorFerrolino, J
dc.contributor.authorAllison, KJ
dc.contributor.authorCross, SJ
dc.contributor.authorEvans, WE
dc.contributor.authorCrews, KR
dc.contributor.authorJeha, S
dc.contributor.authorWolf, J
dc.date.accessioned2020-11-17T03:30:10Z
dc.date.available2020-11-17T03:30:10Z
dc.date.issued2020-09
dc.identifier.citationKarol, S. E., Sun, Y., Tang, L., Pui, C. -H., Ferrolino, J., Allison, K. J., Cross, S. J., Evans, W. E., Crews, K. R., Jeha, S. & Wolf, J. (2020). Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia.. Cancer Med, 9 (18), pp.6550-6555. https://doi.org/10.1002/cam4.3249.
dc.identifier.issn2045-7634
dc.identifier.urihttp://hdl.handle.net/11343/251521
dc.description.abstractBACKGROUND: Fluoroquinolone antibiotics are frequently utilized in pediatric oncology patients as prophylaxis or step-down therapy following broad spectrum beta-lactam therapy for febrile neutropenia. Concerns regarding neurotoxicity limit the use of these agents. No studies have evaluated the association between fluoroquinolone use and neurotoxicity in pediatric oncology patients receiving other neurotoxic agents such as vincristine. METHODS: An observational cohort study comprising patients aged 0-18 at diagnosis enrolled on a prospective study for treatment of acute lymphoblastic leukemia (ALL) at a pediatric comprehensive cancer center between October 2007 and November 2018. Data for neuropathic pain and sensory or motor neuropathy were collected prospectively, and a Cox proportional hazards regression model was used to evaluate associations between administration of fluoroquinolone antibiotics during induction therapy and subsequent development of vincristine-induced peripheral neurotoxicity (VIPN). RESULTS: A total of 598 participants were enrolled, including 338 (57%) who received fluoroquinolones during induction therapy; of these 470 (79%) were diagnosed with VIPN and 139 (23%) were diagnosed with high-grade (Grade 3+) VIPN. On unadjusted analyses, and analyses adjusted for age and race, there was no evidence of an association between fluoroquinolone exposure and subsequent VIPN (hazard ratio [HR] 0.8, 95% CI 0.5-1.04, P = .08) or high-grade VIPN (HR 1.1, 95% CI 0.4-2.2, P = .87). CONCLUSIONS: The results of this observational study do not show an association between exposure to fluoroquinolone antibiotics during induction therapy for ALL and subsequent development of vincristine-induced peripheral neuropathies, and suggest that a large increase in VIPN is unlikely.
dc.languageeng
dc.publisherWiley
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleFluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia.
dc.typeJournal Article
dc.identifier.doi10.1002/cam4.3249
melbourne.affiliation.departmentPaediatrics (RCH)
melbourne.source.titleCancer Medicine
melbourne.source.volume9
melbourne.source.issue18
melbourne.source.pages6550-6555
dc.rights.licenseCC BY
melbourne.elementsid1459311
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520302
melbourne.contributor.authorWolf, Joshua
dc.identifier.eissn2045-7634
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record